Laparoscopic versus open surgery for hepatic caudate lobectomy: a retrospective study.

Autor: Jiang, Zhengchen, Du, Gang, Wang, Xuyang, Zhai, Xiangyu, Zhang, Guangyong, Jin, Bin, Hu, Sanyuan
Předmět:
Zdroj: Surgical Endoscopy & Other Interventional Techniques; Feb2023, Vol. 37 Issue 2, p1149-1156, 8p
Abstrakt: Background: This study was designed to investigate the feasibility and safety of laparoscopic hepatic caudate lobectomy (LHCL) for treating liver tumor by comparing with the open hepatic caudate lobectomy (OHCL). Methods: In the LHCL group, we included 24 patients with liver tumor received LHCL in Qilu Hospital of the Shandong University from January 2014 to January 2019. Meanwhile, 24 matched liver tumor patients underwent OHCL in our hospital served as control. Then we compared the patient characteristics, intraoperative parameters, and postoperative outcomes between LHCL group and OHCL group. Results: There were no significant differences in gender, age, degree of cirrhosis, tumor size, preoperative liver function, Child–Pugh grading, proportion of liver cirrhosis, and tumor size between LHCL group and OHCL group (P > 0.05). No death was reported in both groups. The length of incision in LHCL group was significantly lower than that in OHCL group (4.22 ± 1.14 cm vs. 22.46 ± 4.40 cm, P < 0.001). The intraoperative blood loss in LHCL group was significantly lower than that of OHCL group (116.82 ± 71.61 ml vs. 371.74 ± 579.35 ml, P = 0.047). The total operation time, Pringle maneuver occlusion time, and blocking rate in LHCL group showed no statistical difference compared with those of the OHCL group (P > 0.05). The VAS scores at postoperative 24 and 48 h showed no statistical differences between LHCL group and OHCL group (P > 0.05). Compared with the OHCL group, significant decrease was noticed in the proportion of patients with severe pain 48 h after surgery (0 vs. 4.25 ± 0.46, P < 0.001) and dezocine consumption (90.45 ± 45.77 mg vs. 131.6 ± 81.30 mg, P = 0.0448) in the LHCL group. Conclusion: LHCL is effective and feasible for treating liver tumor, which is featured by reducing intraoperative blood loss and serious pain. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index